Reminder: Roche Virtual Event – Update following ASH 2022 Wednesday 14th December 2022

  We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 14December 2022, highlighting Roche data presented at the American Society of Hematology 2022 Meeting and Exposition, from 10th to 13th December. 16:00 – 17:30 CET / 15:00 - 16:30 GMT10:00 – 11:30 am EST / 7:00 – 8:30 am PST AgendaWelcome -BrunoEschli, Head of Investor RelationsHematology franchise overview -PeterAhnesorg, Franchise Head HematologyReview of key clinical data presented at ASH -Charles Fuchs, Senior Vice President - Global Headof Oncologyand Hematology Product DevelopmentSpark Therapeutics, Inc. (SPK-8011) clinical data update -Gallia G. Levy, MD, PhD, Chief Medical and Product Strategy Officer The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.>click here Access to virtual event (pre-registration required)Please pre-register for our webinarhere*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail [e-mail]. A replay of the webcast will be available via>ir.roche.com *privacy notice  Best regards, Bruno EschliHead of Investor Relations  Loren KalmHead of Investor Relations, North AmericaRoche Investor Relations Dr. BrunoEschliPhone: [phone]e-mail:[e-mail] Dr. SabineBorngr äberPhone: [phone]e-mail:sabine.bo...

Source: Roche Investor Update - December 7, 2022 Category: Pharmaceuticals Source Type: news